Welcome to our dedicated page for Cormedix news (Ticker: CRMD), a resource for investors and traders seeking the latest updates and insights on Cormedix stock.
CorMedix Inc. (Nasdaq: CRMD), also referred to as CorMedix Therapeutics in recent announcements, generates frequent news as a biopharmaceutical company focused on therapeutic products for life-threatening conditions and diseases. Its updates cover commercial performance, clinical development, corporate transactions, and capital markets activity, giving investors and healthcare professionals multiple angles from which to follow the company.
News about CorMedix often highlights the commercial rollout and utilization of DefenCath, an antimicrobial catheter lock solution approved to reduce catheter-related bloodstream infections in certain adult hemodialysis patients using central venous catheters. Press releases have discussed real-world evidence studies with outpatient dialysis organizations, including reductions in infection rates and hospitalizations, as well as recognition such as an Innovative Technology designation from Vizient.
Following its acquisition of Melinta Therapeutics LLC, CorMedix news also covers a broader anti-infective portfolio, including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, along with TOPROL-XL. Investors can expect updates on sales trends, integration progress, and synergy capture related to this transaction. Clinical news includes milestones in the Phase III ReSPECT study of REZZAYO for prophylaxis of invasive fungal disease in allogeneic blood and marrow transplant patients, as well as studies of DefenCath in Total Parenteral Nutrition and pediatric hemodialysis populations.
Regulatory and financial announcements are another important category, such as quarterly and annual results, revenue guidance changes, equity and debt financings, and SEC filings describing material events. Strategic items, including CorMedix’s investment in Talphera and associated board representation and negotiation rights, also appear in the company’s news flow. For investors tracking CRMD, this news page provides a centralized view of earnings releases, clinical data readouts, product designations, conference presentations, and governance updates.
CorMedix Inc. (NYSE American: CRMD) reported a Q1 2020 net loss of $5.6 million ($0.21/share), higher than the $5.2 million loss the previous year. Operating expenses rose 14% to $5.6 million, primarily due to increased SG&A expenses in preparation for a New Drug Application (NDA) for its lead product, Defencath™, which aims to prevent bloodstream infections in hemodialysis patients. The FDA conditionally accepted the proprietary name. The company has cash and short-term investments of $23.2 million, which, along with recent tax benefit sales, gives a pro forma cash total of $31.3 million, sustaining operations into Q2 2021.
CorMedix Inc. (CRMD) announced the appointment of Matt David, M.D. as Executive Vice President and Chief Financial Officer. Dr. David brings extensive experience in healthcare capital markets and strategy, essential for the company as it approaches regulatory approval for Neutrolin, its lead product aimed at preventing bloodstream infections in hemodialysis patients. Neutrolin has demonstrated a 71% reduction in related infections compared to traditional treatments, and it holds FDA Fast Track status. The company has commenced the NDA submission process for the product.
CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company, announced it will report its first-quarter financial results on May 11, 2020, after market close. The company has a focus on developing Neutrolin®, an innovative antimicrobial solution aimed at preventing bloodstream infections related to central venous catheters. The Phase 3 clinical trial for Neutrolin showed a significant 71% reduction in infections compared to heparin controls. Neutrolin holds FDA Fast Track status, and the NDA submission process has commenced. Neutrolin is already CE Marked in Europe.